Sunitinib Malate Capsules 50Mg
Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.
How INAYATAJ Is Given:
As a capsule taken by mouth.
May be taken with or without food. Avoid grapefruit juice.
The amount of Sutent that you will receive depends on several factors, including your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact dosage and schedule.